How do cancer cells avoid complete genetic meltdown?
Scientists from Beijing and Taipei have recently examined HeLa cells to get an insight on cancer vulnerability from a mutational perspective.
Scientists from Beijing and Taipei have examined HeLa cells to get an insight on cancer vulnerability from a mutational perspective.
Famously isolated from cervical cancer victim Henrietta Lacks in 1951, HeLa cells became the first immortalised cell line, helped in the development of the polio vaccine and have become a biotechnology foundational resource for any in vitro drug development or cancer studies.
"In this study, HeLa cells are not used to reveal the process of tumorigenesis but mainly a model for addressing the underlying evolutionary forces, which need to be powerful enough to measure in laboratory settings. We examined variation in growth rate among individual HeLa cells by monitoring clones from a common ancestral HeLa cell population," said corresponding author Xuemei Lu.
They first established a HeLa cell line (E6) derived from an ancestral cell line. When the population size of E6 reached approximately 5 × 104 cells (15~16 divisions), five single-cell clones were generated and established in culture. The team DNA sequenced these clones to catalog the mutations. They focused on copy number variation (CNV) rather than single DNA changes because single-nucleotide mutation rates are too slow to produce significant sequence variation during the short-duration culturing experiments.
"We then estimated the deleterious mutation rate and the average fitness decrease per mutation by performing computer simulations of cell growth," said author Hurng-Yi Wang.
The researchers found that the main mutations affect the copy number of genes, with an average of 0.29 deleterious events for every cell division. Each of these events reduces fitness 18%.
Their results indicate that heterogeneity in cell growth can be generated in a very short period of time in cancer cells and is heritable and genetically determined.
Our estimates indicate that the HeLa cells experience a 5% reduction in fitness for every generation. "Our observations suggest that human cells that have been cultured for a sufficiently long period still generate deleterious mutations in the form of CNVs at a high rate and with a high intensity. For such systems, a mutational meltdown might be plausible."
For example, when they isolated 39 cells from B8 (a fast-growing clone) and 40 cells from E3 (slow growing clone), and monitored their growth from a single cell for seven days, approximately 23% of B8 and 50% of E3 cells died out within seven days, due to either damage caused during cell isolation or genetic defects.
Most cell lines with growth rates <0.6 died within two months. In total, only 60% of B8 and 27% of E3 cells survived for more than two months.
Next, they picked about 20 cells from each of the single cell originated clones from B8 and counted their chromosome numbers.
The chromosomes varied far from the normal human number of 46. They ranged from 38 to 113 chromosomes, with most (72%) cells harbouring between 55 and 70 chromosomes, indicating that they are triploid. Therefore, despite single-cell origin, the progeny quickly generated aneuploidy within only 20–30 cell divisions, again illustrating frequent cytogenetic change in cancer cells.
Despite the level of mutations occurring, reduction in growth rates and chromosome numbers no longer representing that of normal humans, cancer cells still find a way to survive.
"High deleterious mutation rate would raise an impression that the HeLa cell lines may have gone extinct long ago," Lu said.
Their simulation results indicated that although most of the cells accumulated deleterious mutations and were worse than the ancestral cells, there were still 13.1% of cells which were mutation-free.
"These mutation-free cells can avoid the population from extinction."
It also explains why, even if chemotherapy treatment successfully killed 90% of a cancer cell population, it may still not be enough.
The new study not only advances the understanding of the evolution of HeLa cells, and of tumours in general, but of the cells of multicellular organisms in culture in general. In future work, the scientists want to exploit their cancer cell fitness and growth rate findings to understand how cancer cells can become even more vulnerable to recent breakthroughs with checkpoint inhibitor drugs.
An observational study using data covering more than half of the US population suggests that...
Statin therapy is safe and effective in older people over 75 years and reduces major vascular...
Scientists have found that a cellular recycling process called autophagy, previously thought to...